FS Reports最新文献

{"title":"Serum levels of antimüllerian hormone: more than meets the eye","authors":"Kyara Marquez M.D. , Luis R. Hoyos M.D.","doi":"10.1016/j.xfre.2024.02.010","DOIUrl":"10.1016/j.xfre.2024.02.010","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 136-137"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000394/pdfft?md5=af3ecd6938e437b5e1e6d0355490a509&pid=1-s2.0-S2666334124000394-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140462400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of an embryo transfer simulator to compare transfer techniques and pregnancy outcomes among physicians","authors":"Dana B. McQueen M.D. ,&nbsp;Ali Borazjani M.D., Ph.D. ,&nbsp;Chen Yeh M.S. ,&nbsp;Siyuan Dong M.S. ,&nbsp;Magdy P. Milad M.D., M.S. ,&nbsp;Eve C. Feinberg M.D.","doi":"10.1016/j.xfre.2024.04.003","DOIUrl":"https://doi.org/10.1016/j.xfre.2024.04.003","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the association between embryo transfer techniques and pregnancy outcomes.</p></div><div><h3>Design</h3><p>This is a prospective observational study with a retrospective cohort.</p></div><div><h3>Setting</h3><p>University Clinic.</p></div><div><h3>Patients</h3><p>Patients underwent embryo transfers between 2015 and 2020.</p></div><div><h3>Intervention/Exposure</h3><p>Fourteen physicians performed 25 mock embryo transfers on the embryo transfer simulator and completed a questionnaire assessing preferred embryo transfer techniques. Quantitative performance metrics on the embryo transfer simulator were measured. Individual physician embryo transfer success rates were retrospectively collected from all fresh and cryopreserved embryo transfers between January 1, 2015, and January 1, 2020. Associations between embryo transfer techniques (preferred technique and simulator performance metrics) and each physician’s historical patient pregnancy outcomes were assessed.</p></div><div><h3>Main Outcome Measures</h3><p>Associations between embryo transfer techniques and live births were assessed.</p></div><div><h3>Results</h3><p>There were significant differences in embryo transfer techniques between physicians, including touches to the fundus, distance to the fundus, duration of embryo transfer, duration of the complete procedure, time spent navigating the cervical canal, velocity of embryo expulsion, time waited after embryo expulsion, and total score on the embryo transfer simulator. After controlling for confounders and multiple transfers per physician, the duration of embryo transfer was significantly associated with live birth, with longer durations associated with decreased live birth rates. Shorter placement distance to the fundus and higher velocity of embryo expulsion were both significantly associated with higher rates of ectopic pregnancy.</p></div><div><h3>Conclusions</h3><p>This study revealed significant differences in transfer techniques among physicians. The use of the embryo transfer simulator for physicians in practice can elucidate differences and create opportunities for data-driven improvement in embryo transfer success rates.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 183-188"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000503/pdfft?md5=5e67538252a37ddfd46cc9c8971330b9&pid=1-s2.0-S2666334124000503-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141313489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial","authors":"Hugh S. Taylor M.D. ,&nbsp;Liying Dong M.D., Ph.D. ,&nbsp;Johanna Haikonen M.D. ,&nbsp;Peter Oppelt M.D. ,&nbsp;Karl Tamussino M.D. ,&nbsp;Rene Wenzl M.D., Ph.D. ,&nbsp;Thomas Faustmann M.D. ,&nbsp;Esther Groettrup-Wolfers M.D., Ph.D. ,&nbsp;Xiaowei Ren Ph.D. ,&nbsp;Christian Seitz M.D., Ph.D.","doi":"10.1016/j.xfre.2024.03.002","DOIUrl":"10.1016/j.xfre.2024.03.002","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the efficacy and safety of 2 doses of vilaprisan vs. placebo in participants with symptomatic endometriosis.</p></div><div><h3>Design</h3><p>Multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2b trial (NCT03573336). The initially planned sample size was 315 patients. Recruitment was paused to assess long-term toxicity findings in rodents; although the findings were assessed as likely to be of limited clinical relevance in humans, the study was closed by the sponsor. During the pause, enrolled patients completed 3 or 6 months of treatment per their assigned regimen.</p></div><div><h3>Setting</h3><p>University hospitals, a regional hospital, and a private clinic.</p></div><div><h3>Patients</h3><p>Premenopausal adults with confirmed endometriosis and moderate-to-severe pelvic pain (≥4/10 on a numerical rating scale) were enrolled. Inclusion required protocol adherence, including ≥24 diary entries, and an average pain score of ≥3.5.</p></div><div><h3>Intervention</h3><p>Participants were randomly assigned 1:1:1 to receive vilaprisan (2 mg), vilaprisan (4 mg), or placebo.</p></div><div><h3>Main Outcome Measures</h3><p>The primary outcome was a change in the 7-day mean “worst pain” (per the endometriosis symptom diary item 1) from baseline to month 3. All analyses were descriptive only.</p></div><div><h3>Results</h3><p>Eight participants were randomly assigned to treatment before the study pause: 6 received vilaprisan (4 mg, n = 4 and 2 mg, n = 2), and 2 received placebo. The 6 vilaprisan recipients experienced an improvement in endometriosis-associated pelvic pain, whereas the 2 placebo recipients experienced no change or increased pain; all 8 participants had decreased use of pain medication. Bleeding intensity decreased from baseline in the vilaprisan group.</p></div><div><h3>Conclusion</h3><p>The study findings suggest that vilaprisan may improve outcomes in patients with endometriosis. Further studies in larger populations would be needed to accurately assess treatment effects.</p></div><div><h3>Clinical Trial Registration Number</h3><p>NCT03573336</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 2","pages":"Pages 189-196"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000436/pdfft?md5=aef1ec4aeb107210c8b123eaf24560d0&pid=1-s2.0-S2666334124000436-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140272577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first clinical validation of whole-genome screening on standard trophectoderm biopsies of preimplantation embryos","authors":"Yuntao Xia Ph.D. ,&nbsp;Maria Katz M.Sc. ,&nbsp;Dhruva Chandramohan Ph.D. ,&nbsp;Elan Bechor Ph.D. ,&nbsp;Benjamin Podgursky M.Sc. ,&nbsp;Michael Hoxie B.S. ,&nbsp;Qinnan Zhang Ph.D. ,&nbsp;Willy Chertman M.D. ,&nbsp;Jessica Kang B.S. ,&nbsp;Edwina Blue B.S. ,&nbsp;Justin Chen B.S. ,&nbsp;Justin Schleede Ph.D. ,&nbsp;Nathan R. Slotnick M.D., Ph.D. ,&nbsp;Xiaoli Du Ph.D. ,&nbsp;Robert Boostanfar M.D. ,&nbsp;Eric Urcia M.Sc. ,&nbsp;Barry Behr Ph.D. ,&nbsp;Jacques Cohen Ph.D. ,&nbsp;Noor Siddiqui M.Sc.","doi":"10.1016/j.xfre.2024.01.001","DOIUrl":"https://doi.org/10.1016/j.xfre.2024.01.001","url":null,"abstract":"<div><h3>Objective</h3><p>To validate the performance of our laboratory-developed whole-genome screening assay within clinical preimplantation genetic testing environments.</p></div><div><h3>Design</h3><p>Perform a laboratory-developed whole-genome assay on both cell lines and trophectoderm biopsies, subsequently employing the next-generation sequencing procedure to reach a sequencing depth of 30X. Adhere to the Genome Analysis Toolkit best practices for accuracy, sensitivity, specificity, and precision calculations by comparing samples with references. Our assay was then applied to cell lines and biopsies harboring known pathogenic variants, aiming to ascertain these changes solely from the next-generation sequencing data, independent of parental genome information.</p></div><div><h3>Settings</h3><p>Clinical laboratory.</p></div><div><h3>Patients</h3><p>Coriell cell lines and research embryos with known chromosomal or genetic variants. Research trophectoderm biopsies from a couple that are heterozygous carriers for distinct variants in the same autosomal recessive gene (<em>HOGA1</em>).</p></div><div><h3>Intervention</h3><p>Not applicable.</p></div><div><h3>Main Outcome Measures</h3><p>Accuracy, sensitivity, specificity, and precision were assessed by comparing the samples to their references. For samples with known variants, we calculated our sensitivity to detecting established variants. For the research embryos, noncarrier, carrier, and compound heterozygous states of inherited <em>HOGA1</em> variants were distinguished independently of parental samples.</p></div><div><h3>Results</h3><p>Amplification of DNA from cell lines and embryos yielded success rates exceeding 99.9% and 98.2%, respectively, although maintaining an accuracy of &gt;99.9% for aneuploidy assessment. The accuracy (99.99%), specificity (99.99%), sensitivity (98.0%), and precision (98.1%) of amplified genome in the bottle (reference NA12878) and embryo biopsies were comparable to results on genomic DNA, including mitochondrial heteroplasmy. Using our assay, we achieved &gt;99.99% sensitivity when examining samples with known chromosomal and genetic variants. This encompassed pathogenic <em>CFTR</em>, <em>BRCA1</em>, and other variants, along with uniparental isodisomies and microdeletions such as DiGeorge syndrome. Our research study identified noncarrier, carrier, and compound heterozygous states within trophectoderm biopsies while simultaneously screening for 1,300 other severe monogenic diseases.</p></div><div><h3>Conclusion</h3><p>To our knowledge, this is the first clinical validation of whole-genome embryo screening. In this study, we demonstrated high accuracy for aneuploidy calls (&gt;99.9%) and genetic variants (99.99%), even in the absence of parental genomes. This assay demonstrates advancements in genomic screening and an extended scope for testing capabilities in the realm of preimplantation genetic testing.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Pages 63-71"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000011/pdfft?md5=f7473621532958651c70542e0216696c&pid=1-s2.0-S2666334124000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Office of Public Affairs update: a quarterly update from the American Society for Reproductive Medicine Office of Public Affairs on key developments in reproductive health policy","authors":"Rebecca W. O’Connor J.D.","doi":"10.1016/j.xfre.2024.02.003","DOIUrl":"10.1016/j.xfre.2024.02.003","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Page 3"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334124000096/pdfft?md5=7e7b1f4aba17d216bed2becd2c913b39&pid=1-s2.0-S2666334124000096-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139832987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility preservation choices and decisional regret after gender-affirming surgery in transgender men or gender nonbinary persons","authors":"Austin Johnson M.D. ,&nbsp;Asha B. McClurg M.D., M.S.C.R. ,&nbsp;Janine Baldino M.D. ,&nbsp;Rajeshree Das B.A. ,&nbsp;Erin T. Carey M.D., M.S.C.R.","doi":"10.1016/j.xfre.2023.12.002","DOIUrl":"10.1016/j.xfre.2023.12.002","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the prevalence of decisional regret regarding preoperative fertility preservation choices after gender-affirming surgery or removal of reproductive organs.</p></div><div><h3>Design</h3><p>Cross-sectional.</p></div><div><h3>Setting</h3><p>University-based pratice.</p></div><div><h3>Patients</h3><p>A total of 57 survey respondents identifying as transgender men or gender nonbinary with a history of gender-affirming surgery or removal of reproductive organs between 2014 and 2023 with the University of North Carolina Minimally Invasive Gynecology division.</p></div><div><h3>Intervention</h3><p>Survey or questionnaire.</p></div><div><h3>Main Outcome Measures</h3><p>The prevalence and severity of decisional regret regarding preoperative fertility preservation choices were measured with the use of the validated decisional regret scale (DRS) (scored 0–100). Secondary outcomes included patient-reported barriers to pursuing reproductive endocrinology and infertility consultation and fertility preservation treatment.</p></div><div><h3>Results</h3><p>The survey response rate was 50.9% (57/112). “Mild” to “severe” decisional regret was reported by 38.6% (n = 22) of survey respondents, with DRS scores among all respondents ranging from 0–85. Higher median DRS scores were associated with patient-reported inadequacy of preoperative fertility counseling regarding implications of surgery on future fertility or family-building (0 vs. 50) and fertility preservation options (0 vs. 12.5). No desire for future fertility at the time of fertility counseling was the most frequent reason (68.4%) for declining a referral to reproductive endocrinology and infertility for additional fertility preservation discussion.</p></div><div><h3>Conclusions</h3><p>Decisional regret regarding preoperative fertility preservation choices is experienced among transgender men or gender nonbinary persons after gender-affirming surgery or the removal of reproductive organs. Preoperative, patient-centered fertility counseling and fertility preservation treatments should be provided to reduce the risk of future regret.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Pages 87-94"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334123001344/pdfft?md5=df43680816e9ca23df71ee2278096986&pid=1-s2.0-S2666334123001344-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139020896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Involvement of CATSPER 2 mutation in a familial context of unexplained infertility and fertilization failure associated with hearing loss: a case report","authors":"Simon Guignard Ph.D. ,&nbsp;Christina Guillaume M.D. ,&nbsp;Laurie Tornero M.D. ,&nbsp;Jessika Moreau M.D. ,&nbsp;Manon Carles Pharm.D. ,&nbsp;François Isus M.D. ,&nbsp;Éric Huyghe M.D., Ph.D. ,&nbsp;Célia Ravel M.D., Ph.D. ,&nbsp;Nathalie Vergnolle Ph.D. ,&nbsp;Céline Deraison Ph.D. ,&nbsp;Chrystelle Bonnart Ph.D. ,&nbsp;Nicolas Gatimel Pharm.D., Ph.D.","doi":"10.1016/j.xfre.2023.12.003","DOIUrl":"10.1016/j.xfre.2023.12.003","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the functional implications of a homozygous <em>CATSPER 2</em> (cation channel for sperm) deletion within the acrosome reaction pathway during fertilization in 2 brothers, who have unexplained infertility and hearing loss.</p></div><div><h3>Design</h3><p>Case report.</p></div><div><h3>Patients</h3><p>Two twin brothers aged 30 years with hearing loss and unexplained infertility.</p></div><div><h3>Exposure or Intervention</h3><p>Molecular genetic diagnosis of deafness. Evaluation of the acrosome reaction and calcium mobilization assays after induction by progesterone and ionomycin on spermatozoa of the <em>CATSPER 2</em>-mutated patient and on fertile controls.</p></div><div><h3>Main Outcome Measures</h3><p>Fertilization rate during conventional in vitro fertilization. Molecular genetic test. Percentage of acrosome-reacted spermatozoa with peanut agglutinin lectin staining. Recording of progesterone and ionomycin-induced intracellular calcium signals with a fluorescent probe.</p></div><div><h3>Results</h3><p>Mr. S and his brother have normal, conventional sperm parameters. Both brothers have had repeated intrauterine insemination failures and one fertilization failure after conventional in vitro fertilization. Mr. S obtained 2 healthy babies after intracytoplasmic sperm injection. Genetic analysis found a homozygote deletion of the <em>STRC</em> (stereocilin) gene (NM 153700: c.1-? 5328+?del) that removes the <em>CATSPER 2</em> gene. Mutation of the <em>STRC</em> gene is known to be associated with hearing loss. Sperm functional tests revealed an inability of progesterone to activate intracellular calcium signaling and to induce acrosome reaction.</p></div><div><h3>Conclusion</h3><p>We demonstrate the absence of a calcium signal and acrosome reaction after progesterone in our patient with a <em>CATSPER 2</em> mutation. We emphasize the importance of the male medical interview and of the genetic investigation of hearing loss. We show that in vitro fertilization–intracytoplasmic sperm injection is necessary, even where normal sperm parameters are present.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Pages 114-122"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334123001356/pdfft?md5=d8d2ddd4a5d997c4d04a343ad347e0fc&pid=1-s2.0-S2666334123001356-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oocyte cryopreservation and reciprocal in vitro fertilization in a transgender man on long term testosterone gender-affirming hormone therapy: a case report","authors":"Justin White M.D. ,&nbsp;Aaron Jackson M.D. ,&nbsp;Irena Druce M.D., M.Sc. ,&nbsp;Jenna Gale M.D., M.Sc.","doi":"10.1016/j.xfre.2023.11.004","DOIUrl":"10.1016/j.xfre.2023.11.004","url":null,"abstract":"<div><h3>Objective</h3><p>To report a successful case of oocyte cryopreservation and subsequent in vitro fertilization (IVF) in a transgender male receiving continued testosterone gender-affirming hormone therapy, followed by reciprocal embryo transfer (ET).</p></div><div><h3>Design</h3><p>A case report of a rare case of fertility preservation in a transgender man with concomitant use of testosterone therapy for 4 years before and during ovarian stimulation.</p></div><div><h3>Setting</h3><p>Private fertility clinic with university affiliation.</p></div><div><h3>Patient(s)</h3><p>A 26-year-old transgender man undergoing oocyte cryopreservation before gender-affirming surgery.</p></div><div><h3>Intervention(s)</h3><p>Fertility preservation using oocyte cryopreservation and IVF with reciprocal fresh ET into a cisfemale partner.</p></div><div><h3>Main Outcome Measure(s)</h3><p>Successful oocyte cryopreservation, oocyte thawing, and reciprocal IVF cycle.</p></div><div><h3>Result(s)</h3><p>Oocyte cryopreservation of 29 mature oocytes. Sixteen mature oocytes survived the thaw, and 12 were fertilized with intracytoplasmic sperm injection. A fresh ET of an advanced blastocyst resulted in a clinical pregnancy and live birth.</p></div><div><h3>Conclusion(s)</h3><p>Fertility preservation with oocyte cryopreservation or IVF with embryo cryopreservation is feasible for patients on continued long-term testosterone gender-affirming therapy. Future studies on egg quality and reproductive outcomes are required. Our case report demonstrates a promising outcome in this patient population.</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Pages 111-113"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334123001125/pdfft?md5=62260de338948a6fced013b2c9a75d06&pid=1-s2.0-S2666334123001125-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frozen autologous and donor oocytes are associated with differences in clinical and neonatal outcomes compared with fresh oocytes: a Society for Assisted Reproductive Technology Clinic Outcome Reporting System Analysis","authors":"Channing Alexandra Burks M.D. ,&nbsp;Alexandra Purdue-Smithe Ph.D. ,&nbsp;Elizabeth DeVilbiss Ph.D. ,&nbsp;Sunni Mumford Ph.D. ,&nbsp;Rachel Weinerman M.D.","doi":"10.1016/j.xfre.2023.11.003","DOIUrl":"10.1016/j.xfre.2023.11.003","url":null,"abstract":"<div><h3>Objective</h3><p>To study the clinical and neonatal outcomes of embryos derived from frozen oocytes relative to fresh oocytes in both autologous and donor oocyte cycles after fresh embryo transfer (ET).</p></div><div><h3>Design</h3><p>This is a retrospective cohort study using the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database between 2014 and 2015.</p></div><div><h3>Setting</h3><p>The Society for Assisted Reproductive Technology Clinic Outcome Reporting System database was used to identify autologous and donor oocyte cycles that resulted in a fresh ET during 2014 and 2015.</p></div><div><h3>Patients</h3><p>There were 154,706 total cycles identified that used embryos derived from fresh or frozen oocytes and resulted in a fresh ET, including 139,734 autologous oocyte cycles and 14,972 donor oocyte cycles.</p></div><div><h3>Interventions</h3><p>Generalized linear regression models were used to compare the clinical and neonatal outcomes of frozen oocytes relative to fresh oocytes. Models were adjusted for maternal age, body mass index, smoking status, parity, infertility diagnosis, number of embryos transferred, and preimplantation genetic testing. An additional sensitivity analysis was performed to examine singleton pregnancies separately.</p></div><div><h3>Main Outcome Measures</h3><p>The live birth (LB) rate was the primary outcome. Secondary outcomes include pregnancy and birthweight outcomes.</p></div><div><h3>Results</h3><p>Differences in clinical and neonatal outcomes between fresh and frozen-thawed oocytes after fresh ET were observed. Specifically, our study found a higher incidence of high-birthweight infants after the use of frozen oocytes relative to fresh oocytes in both autologous oocytes (12.5% [frozen] vs. 4.5% [fresh], adjusted risk ratio [aRR] 2.67, 95% confidence interval [CI] 1.65–4.3) and donor oocyte cycles (6.2% [frozen] vs. 4.6% [fresh], aRR 1.42, 95% CI 1.1–1.83). This finding remained true when the analysis was restricted to singleton gestations only for both groups: autologous (17.3% [frozen] vs. 7.1% [fresh], aRR 2.77, 95% CI 1.74–4.42) and donor oocytes (9.4% [frozen] vs. 7.8% [fresh], aRR 1.38, 95% CI 1.07–1.77). Additionally, we observed a decrease in LB (aRR 0.81, 95% CI 0.77–0.85); clinical pregnancy (aRR 0.83, 95% CI 0.8–0.87); and an increase in biochemical pregnancy loss (aRR 1.22, 95% CI 1.05–1.43) after the use of frozen oocytes in donors, but not autologous cycles.</p></div><div><h3>Conclusions</h3><p>Our findings of an increased incidence of high-birthweight infants after the transfer of embryos derived from frozen oocytes in both autologous and donor oocyte cycles raise questions about oocyte vitrification and deserve further study. Additionally, the finding of a decreased likelihood of LB with frozen-donor oocytes compared with fresh donor oocytes is an important finding, especially because more patients are seeking to use frozen oocytes in their donor egg cycl","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Pages 40-46"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334123001113/pdfft?md5=36616cbef72621a9dbbf52a27de954a8&pid=1-s2.0-S2666334123001113-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of the minimal cyclophosphamide equivalent dose and outcome of microdissection testicular sperm extraction in patients with persistent azoospermia after chemotherapy","authors":"I-Shen Huang M.D. ,&nbsp;Richard J. Fantus M.D. ,&nbsp;Joshua A. Halpern M.D. ,&nbsp;James Wren M.D. ,&nbsp;Nelson E. Bennett M.D. ,&nbsp;Minh Nguyen Pham M.D. ,&nbsp;Alexander Stanisic M.D. ,&nbsp;William J. Huang M.D., Ph.D. ,&nbsp;Robert E. Brannigan M.D.","doi":"10.1016/j.xfre.2023.11.005","DOIUrl":"10.1016/j.xfre.2023.11.005","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate whether the minimal cyclophosphamide equivalent dose (mCED), a novel approach for estimating alkylating agent exposure, is associated with the sperm retrieval rates by microdissection testicular sperm extraction (mTESE) in azoospermic postchemotherapy cancer survivors.</p></div><div><h3>Design</h3><p>A retrospective cohort study conducted between 2002 and 2017.</p></div><div><h3>Setting</h3><p>An academic medical center.</p></div><div><h3>Patients</h3><p>A total of 28 azoospermic postchemotherapy cancer survivors who underwent mTESE.</p></div><div><h3>Interventions</h3><p>Chemotherapy exposure and mCED calculation.</p></div><div><h3>Main Outcome Measures</h3><p>The primary outcome was the association between the mCED and sperm retrieval rate using mTESE. The mCED value for each patient’s regimen received was estimated using the lowest recommended dosing regimen from the range of recommended doses at the time of administration.</p></div><div><h3>Results</h3><p>Spermatozoa were successfully retrieved in 11 (39.3%) of the patients. Age at the time of receiving chemotherapy and mCED were significant factors associated with sperm retrieval. An mCED of &lt;4,000 mg/m² had a higher sperm retrieval rate (10/14, 71.4%) than an mCED of &gt;4,000 mg/m² (0/8, 0). The hormone levels were not significantly different when comparing patients with and without successful sperm retrieval. Seminoma, nonseminomatous germ cell tumor, and acute lymphoblastic leukemia had favorable sperm retrieval rates—100% (2/2), 66.7% (2/3), and 66.7% (2/3), respectively—although the numbers of patients in each group were small.</p></div><div><h3>Conclusion</h3><p>Among this cohort of patients with cancer who required chemotherapy regimens, successful sperm retrieval by mTESE was only noted among cancer survivors receiving an mCED of &lt;4,000 mg/m².</p></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"5 1","pages":"Pages 95-101"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666334123001137/pdfft?md5=175b0ec3127170854c480d944fae3950&pid=1-s2.0-S2666334123001137-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135764397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}